ReviewJournal of personalized medicine2021
Of Screening, Stratification, and Scores.
Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Polygenic risk scores in the clinic: a systematic review of stakeholders' perspectives, attitudes, and experiences.European journal of human genetics : EJHG · 2025Pooled it
- AI-driven integration of genomic and exposome data for cancer risk: the combined risk score (CRS).Human genomics · 2026Review
- Deep learning driven clustering of post-traumatic stress disorder (PTSD) profiles in student-athletes: implications for precision and stratified mental health support.BMC psychology · 2026Article
- Clinical use of polygenic risk scores: current status, barriers and future directions.Nature reviews. Genetics · 2026Review
- Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements.iScience · 2026Review
- Barriers and enablers for health system reform.Frontiers in health services · 2026Article
- The Pittsburgh sleep quality index-2 (PSQI-2): the validity of a two-item sleep quality screener in Brazilian adults.Sleep & breathing = Schlaf & Atmung · 2025Article
- Enhancing cancer risk awareness and screening management through artificial intelligence: a narrative review.Frontiers in oncology · 2025Review
- Mapping the state-of-the-art of the barriers for personalized preventive approaches worldwide: A scoping review of reviews.PloS one · 2025Article
- Review
- Ethical Dimensions of Population-Based Lung Cancer Screening in Canada: Key Informant Qualitative Description Study.Public health ethics · 2024Article
- Value proposition of retinal imaging in Alzheimer's disease screening: A review of eight evolving trends.Progress in retinal and eye research · 2024Review
- A proposal for an inclusive working definition of genetic discrimination to promote a more coherent debate.Nature genetics · 2024Review
- Recent advances in polygenic scores: translation, equitability, methods and FAIR tools.Genome medicine · 2024Review
- Navigating the uncertainty of precision cancer screening: The role of shared decision-making.PEC innovation · 2023Article
- Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores.Journal of community genetics · 2023Article
- Regulating cancer risk prediction: legal considerations and stakeholder perspectives on the Canadian context.Human genetics · 2023Article
- Ethical layering in AI-driven polygenic risk scores-New complexities, new challenges.Frontiers in genetics · 2023Article
- Personalized Approaches for the Prevention and Treatment of Breast Cancer.Journal of personalized medicine · 2022Article
- Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.Current oncology (Toronto, Ont.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Technological innovations including risk-stratification algorithms and large databases of longitudinal population health data and genetic data are allowing us to develop a deeper understanding how individual behaviors, characteristics, and genetics are related to health risk. The clinical implementation of risk-stratified screening programmes that utilise risk scores to allocate patients into tiers of health risk is foreseeable in the future. Legal and ethical challenges associated with risk-stratified cancer care must, however, be addressed. Obtaining access to the rich health data that are required to perform risk-stratification, ensuring equitable access to risk-stratified care, ensuring that algorithms that perform risk-scoring are representative of human genetic diversity, and determining the appropriate follow-up to be provided to stratification participants to alert them to changes in their risk score are among the principal ethical and legal challenges. Accounting for the great burden that regulatory requirements could impose on access to risk-scoring technologies is another critical consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.